Alpha 2.0
Login Register
» Authors » Mikio Kido

Mikio Kido

Explore the profile of Mikio Kido including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 55
Citations 506
Followers 0
Related Specialties
Psychiatry
Neurology
Pharmacology
Top 10 Co-Authors
Tsutomu Takahashi
Michio Suzuki
Kyo Noguchi
Atsushi Furuichi
Yoichiro Takayanagi
Daiki Sasabayashi
Mihoko Nakamura
Yumiko Nishikawa
Ryota Hashimoto
Norio Yasui-Furukori
Published In
Front Psychiatry
Psychiatry Clin Neurosci
Prog Neuropsychopharmacol Biol Psychiatry
Schizophr Res
Cereb Cortex
Affiliations
Soon will be listed here.
Recent Articles
1.
The relationship between gray/white matter contrast and cognitive performance in first-episode schizophrenia
Kobayashi H, Sasabayashi D, Takahashi T, Furuichi A, Kido M, Takayanagi Y, et al.
Cereb Cortex . 2024 Jan; 34(2). PMID: 38265871
Previous postmortem brain studies have revealed disturbed myelination in the intracortical regions in patients with schizophrenia, possibly reflecting anomalous brain maturational processes. However, it currently remains unclear whether this anomalous...
2.
Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study
Hasegawa N, Yasuda Y, Yasui-Furukori N, Yamada H, Hori H, Ichihashi K, et al.
Psychiatry Clin Neurosci . 2023 Sep; 77(10):559-568. PMID: 37684711
Aim: This study aims to examine the real-world effectiveness of education regarding clinical guidelines for psychiatric disorders using 'the Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)'...
3.
Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project
Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Hori H, Iida H, et al.
BMC Psychiatry . 2023 Jun; 23(1):473. PMID: 37380997
Background: Polypharmacy of additional psychotropics alongside the main treatment drug (antipsychotics in schizophrenia and antidepressants in major depressive disorder) is common in Japan. Our goal is to align psychotropic prescription...
4.
Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan
Onitsuka T, Okada T, Hasegawa N, Tsuboi T, Iga J, Yasui-Furukori N, et al.
J Clin Psychopharmacol . 2023 May; 43(4):365-368. PMID: 37216369
Background: Although several guidelines recommend monotherapy with antipsychotics for the treatment of schizophrenia, patients who receive long-acting injectable antipsychotics (LAIs) are frequently treated with oral antipsychotics (OAPs). In the present...
5.
The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in...
Kyou Y, Yasui-Furukori N, Hasegawa N, Ide K, Ichihashi K, Hashimoto N, et al.
Ann Gen Psychiatry . 2022 Dec; 21(1):52. PMID: 36567327
Background: Several guidelines recommend monotherapy in pharmacotherapy for schizophrenia and major depressive disorder. The content of regular prescriptions has been reported in several studies, but not enough research has been...
6.
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders
Fukumoto K, Kodaka F, Hasegawa N, Muraoka H, Hori H, Ichihashi K, et al.
Neuropsychopharmacol Rep . 2022 Nov; 43(1):33-39. PMID: 36394160
Aim: Treatment guidelines are designed to assist patients and health care providers and are used as tools for making treatment decisions in clinical situations. The treatment guidelines of the Japanese...
7.
Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia"
Inada K, Fukumoto K, Hasegawa N, Yasuda Y, Yamada H, Hori H, et al.
Neuropsychopharmacol Rep . 2022 Oct; 42(4):502-509. PMID: 36254805
Aims: The Guidelines for the Pharmacotherapy of Schizophrenia were established to improve the quality of medical care, and the EGUIDE project was conducted to train clinicians on guideline usage. A...
8.
Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score-matched analysis
Tsuboi T, Takaesu Y, Hasegawa N, Ochi S, Fukumoto K, Ohi K, et al.
Psychiatry Clin Neurosci . 2022 Oct; 77(1):30-37. PMID: 36215112
Aim: We investigated the association of electroconvulsive therapy (ECT) with anxiolytic and sleep medication use in patients with major depressive disorder (MDD) and schizophrenia (SZ). Methods: This nationwide observational study...
9.
Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia
Okada T, Hori H, Hasegawa N, Murata A, Kyou Y, Kodaka F, et al.
J Clin Psychopharmacol . 2022 Oct; 42(6):591-593. PMID: 36193896
No abstract available.
10.
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study
Ochi S, Tagata H, Hasegawa N, Yasui-Furukori N, Iga J, Kashiwagi H, et al.
Int J Neuropsychopharmacol . 2022 Jun; 25(10):818-826. PMID: 35723038
Background: Although clozapine is effective for treatment-resistant schizophrenia (TRS), the rate of clozapine prescription is still low. Whereas antipsychotic monotherapy is recommended in clinical practice guidelines, the rate of antipsychotic...